Q-omics provides the consensus-scored LY6H profile across patient tissues and cancer cell-line models. LY6H expression is associated with patient survival in 26 of 34 cancer types, with the highest sampling consensus in LUSC. Among the 18 cancer types available for tumor–normal comparison, LY6H is differentially expressed in 12, with the highest sampling consensus in KIRC. Additionally, LY6H RNA expression shows 16,530 significant protein co-abundance associations, with the highest sampling consensus in GBM. Together, these results highlight LUSC, KIRC, and GBM as cancer lineages where LY6H shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for LY6H — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes LY6H survival associations across molecular data types. LY6H RNA expression shows survival associations in the most cancer types (26), followed by mutation status (1) and mass-spec protein abundance (3). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible LY6H RNA expression–survival associations across cancer types. High LY6H expression shows unfavorable associations in LUSC, LIHC, KIRP, LUAD, UCS and OV. The LUSC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify LUSC as the clearest survival context for LY6H RNA expression.
This table summarizes LY6H tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 12, while mass-spec protein shows differences in 1. The strongest signals are observed in KIRC for RNA and LUAD for protein.
This table ranks reproducible tumor–normal expression differences for LY6H. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. LY6H shows lower tumor expression in STAD and COAD and higher tumor expression in KIRC, LIHC, BRCA and CHOL. The KIRC box plot shows higher LY6H RNA expression in tumor versus normal tissue (log2 FC = +1.160, t-test p < 0.001).
This table shows molecular features associated with LY6H in patient tissues and cancer cell lines. In patient samples, LY6H shows the broadest associations at the RNA and protein expression levels, with GBM recurring as the lineage with the largest associated feature set. In cancer cell lines, LY6H RNA and mutation anchors are most strongly linked to RNA-expression features, especially in UPPER_AERODIGESTIVE_TRACT, while CRISPR and shRNA rows add functional-dependency signals in BONE and LUNG_NSCLC_LUAD.
